Please click here and read carefully the summary of the key features and risks specific to this fund stated in the offering document prepared by the relevant fund house before making any investment decision.
You should not rely solely on the information contained on this webpage to make investment decisions. You should read carefully and understand the relevant fund's offering documents before making any investment decision.
| Year | Total | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
| 2026 | - | 0.8% | 2.0% | -6.5% | - | - | - | - | - | - | - | - | - |
| 2025 | 24.5% | 5.9% | -0.3% | -4.5% | -0.3% | -5.7% | 2.3% | -0.9% | 6.1% | 2.7% | 8.8% | 9.4% | -0.1% |
| 2024 | 3.3% | 2.8% | 3.8% | 1.7% | -4.7% | 3.5% | 3.2% | 2.6% | 5.2% | -2.4% | -3.3% | -0.7% | -7.6% |
| 2023 | 7.0% | 0.4% | -4.3% | 2.6% | 4.0% | -2.3% | 3.1% | 1.0% | -1.4% | -3.9% | -6.3% | 7.4% | 7.6% |
| 2022 | -2.9% | -8.9% | 0.5% | 3.5% | -6.8% | -0.9% | -0.8% | 3.7% | -2.6% | -2.9% | 8.4% | 6.0% | -0.8% |
| Load more | 5 of 14 | ||||||||||||
| Eli Lilly and Co | 9.38% |
| Johnson & Johnson | 6.93% |
| AstraZeneca PLC | 4.62% |
| AbbVie Inc | 3.84% |
| UnitedHealth Group Inc | 3.13% |
| Novartis AG ADR | 2.96% |
| Abbott Laboratories | 2.55% |
| Roche Holding AG | 2.50% |
| Praxis Precision Medicines Inc Ordinary Shares | 2.41% |
| argenx SE ADR | 2.37% |
| Thermo Fisher Scientific Inc | 2.29% |
| Vertex Pharmaceuticals Inc | 2.16% |
| Boston Scientific Corp | 2.09% |
| Intuitive Surgical Inc | 2.07% |
| HCA Healthcare Inc | 2.03% |
Warning statements
Risk Warnings Investment involves risk. Past performance is not an indicator nor a guarantee of future performance or returns. Projected performance or returns are not guaranteed to materialise. The value of investments and the income from them can go down as well as up, and you may not get the full amount you invested. Rates of exchange may cause the value of investments to go up or down. Individual stock performance does not represent the return of a fund.
The value of the fund can be volatile and can go down substantially within a short period of time. It is possible that a certain amount or all of your investment could be lost.
Generic risk warnings relating to collective investment schemes
Funds are not a bank deposit and not capital guaranteed, and is subject to investment risks, including the possible loss of the principal amount invested. There is no assurance that a fund will have sufficient liquidity to meet redemption requests and that the fund's investment objectives and strategies will be achieved.
The funds' investment may involve substantial market, currency, volatility, liquidity, regulatory and political risks. Some funds may use derivatives, whether for hedging or for investment purposes. The risks associated with derivatives include counterparty/credit, liquidity, valuation, volatility and market risks. The fund's volatility may increase or decrease from its derivative usage and such fund may suffer losses from its derivative usage. Do not invest in these funds unless you fully understand and are willing to assume the risks associated with them.
Opinions Any forward-looking statements, prediction, projection or forecast on the economy, stock market, bond market or economic trends of the markets contained in this material are subject to market influences and contingent upon matters outside the control of Endowus HK Limited (“Endowus”) and therefore may not be realised in the future. Further, any opinion or estimate is made on a general basis and subject to change without notice. In presenting the information above, none of Endowus HK Limited, its affiliates, directors, employees, representatives or agents have given any consideration to, nor have made any investigation of the objective, financial situation or particular need of any user, reader, any specific person or group of persons. Therefore, no representation is made as to the completeness and adequacy of the information to make an informed decision. You should carefully consider (i) whether any investment views and products/ services are appropriate in view of your investment experience, objectives, financial resources and relevant circumstances. You may also wish to seek financial advice through a financial advisor or the Endowus platform and independent legal, accounting, regulatory or tax advice, as appropriate.
Third party content ©2025 Morningstar. All Rights Reserved. The information contained here relating to a particular collective investment scheme: (1) is proprietary to Morningstar Research Pte. Limited and/or its content providers (“Information Provider(s)“) unless otherwise specified; and (2) may not be copied or distributed. Neither the Information Provider nor Endowus guarantee or endorse the accuracy, reliability, completeness or timeliness of the information, or are responsible for any damages or losses arising from any use of this information. Further, for technical reasons, certain information provided by Information Provider may be different from that supplied by the respective fund houses.
No invitation or solicitation Nothing contained on this webpage should be construed as a solicitation, recommendation or an offer by Endowus or any of its affiliates to buy or sale any security, commodity, investment or to engage in any other transaction in any jurisdiction in which such solicitation, recommendation or offer to buy or sale would be unlawful under the securities laws in such jurisdiction. No information included on this webpage is to be construed as investment advice or as a recommendation or a representation about the suitability or appropriateness of any advisory product or service; or an offer to buy or sell, or the solicitation of an offer to buy or sell, any security, financial product, or instrument; or to participate in any particular trading strategy. Investors should seek independent financial and tax advice before making any investment decision.
Product Risk Rating Please note that any product risk rating (the “PRR”) provided by us is an internal rating assigned based on our product risk assessment model, and is for your reference only. The PRR is subject to change from time to time. The PRR does not take into account your individual circumstances, objectives or needs and should not be regarded as advice or recommendation to purchase, hold or sell any fund or make any other investment decisions. Accordingly, you should not solely rely on the PRR in making your investment decision in the relevant Fund.
The contents of this webpage have not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong.
Disclaimer:
General This website has been prepared by Endowus HK Limited ("Endowus"), which is licensed (CE No. BQR225) by the Securities and Futures Commission (the "SFC") in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) to carry on business in Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities. You can verify this information on the SFC's website here.
Jurisdictional Disclaimers By accessing this website, you acknowledge that you are a resident of Hong Kong. This website is not intended for U.S. Persons and should not be accessed by persons located or resident any other jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local laws or regulations or would subject Endowus to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licences, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your access to this website.
The content contained in this website has not been reviewed by the SFC or any regulatory authority in Hong Kong and are subject to the Privacy Policy and the full disclaimer found here.